Ketalar
ApprovedSmall molecule
Ketalar is one of 120 small molecule programs targeting Agitation. It is currently in Approved.
5
Indications
6
Total Trials
1
Active Trials
119
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
193 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Ketalar
HHelse Møre og Romsdal HF
Approved
Tapentadol ER
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Buprenorphine IV
PPurdue Pharma LP
Phase 3
Opana
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
BEMA Fentanyl
BBioDelivery Sciences International
Phase 3
MS Contin
Merck & Co.Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Dayvigo
EisaiPreclinical
Intuniv
PPromius Pharma, LLC
Preclinical
Glucophage
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tendinopathy1 trial
Hypotension1 trial
Ketamine vs Ephedrine on Post Spinal Hypotension in Caesarean Delivery
Completed·—·Phase 1·NCT07034911·100 enrolled
1 more indication
Dexmedetomidine1 trial
Effect of Ketalar or Dexmedetomidine on Increased Sensitivity to Pain Following Treatment With Remifentanil
Recruiting·—·N/A·NCT06473896·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ketalar. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- HHelse Møre og Romsdal HF